Clinical Trial Update: Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Gefitinib in patients with recurrent and/or metastatic head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED